Results for underlying liver translation from English to Maltese

the safety and efficacy of stavudine has not been established in patients with significant underlying liver
is- sigurtà u l- effikaċja ta ’ stavudine għadhom ma ġewx stabbiliti f’ pazjenti li għandhom mard tal- fwied sinifikanti.

the safety and efficacy of kivexa has not been established in patients with significant underlying liver disorders.
is-sigurtà u l-effikaċja ta’ kivexa ma ġewx stabbiliti f’pazjenti b’mard sinifikanti tal-fwied.

an increased incidence of nephrolithiasis has been observed in patients with underlying liver disorders when treated with indinavir.
Ġiet osservata inċidenza ikbar ta’ nefrolitjasis f’pazjenti li għandhom mard sustanti fil-fwied meta kkurati b’indinavir.

the safety and efficacy of lamivudine and raltegravir have not been established in patients with severe underlying liver disorders.
is-sigurtà u l-effikaċja ta’ lamivudine u raltegravir ma ġewx determinati f’pazjenti b’disturbi inerenti serji tal-fwied.

the safety and efficacy of lopinavir/ritonavir has not been established in patients with significant underlying liver disorders.
is-sigurtà u l-effikaċja ta’ lopinavir/ritonavir għada ma ġietx stabbilita f’pazjenti bi problemi tal-fwied li huma sinifikanti iżda mhux immedjatament ovvji.

liver disease: the safety and efficacy of amprenavir has not been established in patients with significant underlying liver disorders.
mard tal-fwied: is-sigurtà u l-effikaċja marbutin ma’ l-użu ta’ agenerase f’pazjenti li jbatu minn mard serju fil-fwied m’humiex magħrufa.

liver disease: the safety and efficacy of enfuvirtide has not been specifically studied in patients with significant underlying liver disorders.
mard tal-fwied: is-sigurtà u l-effikaċja ta’ enfuvirtide f’pazjenti b’disturbi sottostanti sinifikanti tal- fwied ma ġewx studjati speċifikament.

the safety and efficacy of prezista have not been established in patients with severe underlying liver disorders and prezista is therefore contraindicated in patients with severe hepatic impairment.
is-sigurtà u l-effikaċja ta’ prezista ma’ ġewx stabbiliti f’pazjenti b’mard serju tal-fwied u għalhekk prezista huwa kontra-indikat f’pazjenti b’indeboliment epatiku serju.

the pharmacokinetics, safety and efficacy of atripla have not been established in patients with significant underlying liver disorders (see section 5.2).
il-farmakokinetika, is-sigurtà u l-effikaċja ta’ atripla ma ġewx stabbiliti f’pazjenti b’disturbi sinifikanti diġà eżistenti tal-fwied (ara sezzjoni 5.2).

the safety and efficacy of descovy in patients with significant underlying liver disorders have not been established (see sections 4.2 and 5.2).
is-sigurtà u l-effikaċja ta’ descovy f’pazjenti b’disturbi tal-fwied sottostanti sinifikanti ma ġewx stabbiliti (ara sezzjonijiet 4.2 u 5.2).

there have been reports of exacerbation of chronic liver dysfunction, including portal hypertension, in patients with underlying hepatitis b or c, cirrhosis and other underlying liver abnormalities.
kien hemm rapporti ta ’ aggravar ta ’ abnormalità kronika tal- fwied, li tinkludi pressjoni għoljaportali, f’ pazjenti b’ epatite b jew c prinċipali, ċirrożi u abnormalitajiet prinċipali oħrajn tal- fwied.

experience with tocofersolan therapy in patients with renal impairment or underlying liver impairment has demonstrated no need to adapt the dose regimen of vedrop (see section 4.4).
l-esperjenza bit-terapija b’tocofersolan f’pazjenti b’indeboliment tal-kliewi jew indeboliment tal-fwied preżenti wriet li ma hemm ebda bżonn ta’ adattament tal-iskeda tad-dożaġġ ta’ vedrop (ara s-sezzjoni 4.4).

the safety and efficacy of saquinavir/ ritonavir has not been established in patients with significant underlying liver disorders, therefore saquinavir/ ritonavir should be used cautiously in this patient population.
is- sigurtà u l- effikaċja ta ’ saquinavir/ ritanovir ma kinetx stabbilita f’ pazjenti b’ mard prinċipali sinifikattiv tal- fwied, għalhekk saquinavir/ ritanovir għandu jintuża b’ attenzjoni f’ din il - popolazzjoni ta ’ pazjenti.

26 rare cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions.
reazzjonjiet epatiċi Ġew irrapurtati każijiet rari ta ’ insuffiċjenza akuta tal- fwied f’ pazjenti li kienu qed jieħdu medikazzjoni multipla fl- istess ħin u b’ kondizzjonijiet mediċi serji sottostanti.

liver disease: the safety and efficacy of saquinavir/ritonavir has not been established in patients with significant underlying liver disorders, therefore saquinavir/ritonavir should be used cautiously in this patient population.
mard tal-fwied: is-sigurtà u l-effikaċja ta’ saquinavir/ritanovir ma kinetx stabbilita f’pazjenti b’mard prinċipali sinifikattiv tal-fwied , għalhekk saquinavir/ritanovir għandu jintuża b’attenzjoni f’din il- popolazzjoni ta’ pazjenti.

in these patients, confounding factors have included pre-existing liver disease and/or comorbidities associated with progression of underlying malignancy.
f’dawn il-pazjenti, fatturi li jfixlu kienu jinkludu mard tal-fwied li kien jeżisti minn qabel u/jew komorbożitajiet assoċjati mal-progressjoni tat-tumur malinn li kien jeżisti minn qabel.

pre-existing lamivudine-resistant hbv is associated with an increased risk for subsequent entecavir resistance regardless of the degree of liver disease; in patients with decompensated liver disease, virologic breakthrough may be associated with serious clinical complications of the underlying liver disease.
hbv reżistenti għal lamivudine pre-eżistenti hija assoċjata ma’ żieda fir-riskju għal reżistenza għal entecavir sussegwenti minkejja l-grad tal-marda tal-fwied; f’pazjenti b’marda tal-fwied mhux stabbli, il-breakthrough viroloġiku jista’ jkun assoċjat ma’ kumplikazzjonijiet klinikament serji tal-marda prinċipali tal-fwied.

increased monitoring (i. e. prior to initiation of therapy, every two weeks during the first three months of treatment, then monthly until 48 weeks, and then every eight to twelve weeks thereafter) is warranted when aptivus and low dose ritonavir are administered to patients with elevated asat and alat levels, mild hepatic impairment, chronic hepatitis-b or – c or other underlying liver disease.
4 l- ewwel tliet xhur ta 'trattament, sa 48 ġimgħa, u mbagħad kull tmin sa tnax- il ġimgħa wara dan) huwa meħtieġ li jsir meta aptivus u doża baxxa ta' ritonavir huma amministrati lil pazjenti li għandhom livelli ta 'asat u alat ogħljin, indeboliment ħafif tal- fwied, epatite b jew Ċ kronika jew mard tal- fwied fl- isfond.